Overview

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Phase:
PHASE3
Details
Lead Sponsor:
Kailera